On September 20, 2019 AskAt reported that it received a notice of allowance dated August 13, 2019 from the Mexican Institute of Industrial Property (IMPI: Instituto Mexicano de la Propiedad Industrial) in connection with the Mexican Patent Application No. MX/a/2016/008394, a use patent of EP4 receptor antagonist for the treatment of cancer (Press release, AskAt, SEP 20, 2019, View Source [SID1234539659]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!